sb 202190 has been researched along with Granulocytic Leukemia, Chronic in 2 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, C | 1 |
| Olsen, JV | 1 |
| Daub, H | 1 |
| Mann, M | 1 |
| Colosetti, P | 1 |
| Puissant, A | 1 |
| Robert, G | 1 |
| Luciano, F | 1 |
| Jacquel, A | 1 |
| Gounon, P | 1 |
| Cassuto, JP | 1 |
| Auberger, P | 1 |
2 other studies available for sb 202190 and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Topics: Butadienes; Dasatinib; Databases, Protein; Epidermal Growth Factor; Fusion Proteins, bcr-abl; HeLa C | 2009 |
Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line.
Topics: Autophagy; Cell Differentiation; Humans; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR | 2009 |